Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM)
Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells
Sponsor: Centre Oscar Lambret
Terminated
The failures of the culture and immunostaining techniques for ALDH do not allow the main objective of the study to be met.
Other terminated trials from Centre Oscar Lambret
This NA trial investigates Breast Cancer and is currently terminated or withdrawn. Centre Oscar Lambret leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2024 [monthly]
Terminated NA
-
Nov 2021 — Dec 2021 [monthly]
Terminated NA
Status: Unknown Status → Terminated
-
Jan 2021 — Nov 2021 [monthly]
Unknown Status NA
▶ Show 3 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jun 2018 — Oct 2020 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Oscar Lambret
- Institut National de la Santé Et de la Recherche Médicale, France
- Institut pour la Recherche sur le Cancer de Lille
For direct contact, visit the study record on ClinicalTrials.gov .